Genentech ( Genentech )


Genentech's picture

About Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.

Genentech press release, blog etc

11/12/2018 - 10:37 FDA Grants Priority Review to Genentechs Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
10/31/2018 - 14:26 Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
10/27/2018 - 11:11 New STAIRWAY Study Data Shows Potential for Extended Durability With Faricimab in Wet Age-Related Macular Degeneration (AMD)
10/23/2018 - 23:32 Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
10/22/2018 - 08:34 Genentechs Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
10/20/2018 - 20:51 Genentechs Investigational Personalized Medicine Entrectinib Shrank Tumors in People With NTRK Fusion-Positive Solid Tumors
10/19/2018 - 20:22 Genentechs Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
10/19/2018 - 08:20 FDA Approves Label Update for Genentechs Rituxan (Rituximab) in Two Rare Forms of Vasculitis
10/14/2018 - 16:56 Genentechs Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
10/09/2018 - 16:14 OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
10/03/2018 - 18:01 FDA Approves Genentechs Hemlibra (Emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
10/02/2018 - 17:32 Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
10/01/2018 - 13:43 Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
09/28/2018 - 03:57 FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation
09/25/2018 - 02:43 Genentechs TECENTRIQ in Combination With Chemotherapy Helped People Live Significantly Longer as an Initial Treatment for People With Extensive-Stage Small Cell Lung Cancer
09/24/2018 - 02:10 Genentechs TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung Cancer
09/24/2018 - 01:42 Genentechs Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer
09/13/2018 - 17:58 FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis